479 Results

FDA accepts BLA for tildrakizumab, a proposed treatment for psoriasis.- Sun Pharma.

 Added 4 days ago

Sun Pharmaceutical Industries Ltd announces the FDA acceptance of the Biologics License Application (BLA) for tildrakizumab. The FDA filing acceptance...

EU CHMP recommends refusal on application of Masipro (masitinib) in systemic mastocytosis- AB Science

 Added 8 days ago

The Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation...

EU CHMP recommends approval of Siliq (brodalumab) for patients with moderate-to-severe plaque psoriasis- LEO Pharma

 Added 9 days ago

LEO Pharma has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European...

Phase III study of Nucala (mepolizumab) in Eosinophilic Granulomatosis with Polyangiitis published in NEJM- GlaxoSmithKline

 Added 10 days ago

GlaxoSmithKline has announced publication in the New England Journal of Medicine, of a randomised, double-blind, placebo controlled study investigating the...

The 76th Annual Meeting of the Society for Investigative Dermatology is underway in Portland, Oregon, USA

 Added 1 month ago

The 76th Annual Meeting of the Society for Investigative Dermatology is underway in Portland, Oregon, USA

The 76th Annual Meeting of the Society for Investigative Dermatology (SID) takes place 26─29 April in Portland, Oregon, in the United States.

The first patient has now been enrolled into "EASE", the pivotal Phase III clinical trial which is evaluating AP 101 as a potential treatment for the rare, genetic skin disorder, Epidermolysis Bullosa.- Amryt.

 Added 1 month ago

Amryt, is pleased to announce that the first patient has now been enrolled into "EASE", the Company's pivotal Phase III...

Valeant Pharmaceuticals International announces marketing information for Siliq (brodalumab), a new treatment for psoriasis.

 Added 1 month ago

Valeant Pharmaceuticals International, Inc. announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the...

The XII International Society of Dermatology kicks off congress in Buenos Aires, Argentina

 Added 1 month ago

Congress President Ricardo Galimberti opens proceedings to over 6,000 delegates.

UK NICE gives final appraisal recommending use of Cosentyx (secukinumab) in psoriatic arthritis- Novartis

 Added 1 month ago

The UK's National Institute for Health and Care Excellence has published its final appraisal which backs the use of Cosentyx...

Positive Phase III REVIVE-1 study of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).- Motif Bio.

 Added 1 month ago

Motif Bio plc announced positive topline results from REVIVE-1, a global Phase III clinical trial of its investigational drug candidate...

Load more